

Cumulative Index 1989

Volume 10

| | |
|-----------|--|
| March | METABOLIC FUNCTIONS OF THE LUNGS, pages 1-128 |
| June | PULMONARY FUNCTION TESTING, pages 129-296 |
| September | MYCOBACTERIAL DISEASES, pages 297-467 |
| December | PULMONARY MANIFESTATIONS OF SYSTEMIC DISEASE, pages 469-818 |

Note: Page numbers of issues and articles are in boldface type.

- A-56268, in treatment of tuberculosis, 358
Abdominal muscles, role in respiratory muscle function, 201
Achalasia, pulmonary manifestations of, 621
Acquired immunodeficiency syndrome (AIDS), effect on immunity, 507
mycobacterial disease in patients with, 445-463
nontuberculous mycobacterial infection in, 456-460.
See also *Mycobacterial infection, nontuberculous, in AIDS*.
tuberculosis in, 308-309, 447-456. See also *Tuberculosis, in AIDS*.
Acute lung injury, effect on pulmonary metabolic function, 7-9
effects of sepsis on, 493
respiratory tract infections and, in systemic illness, 469-502
systemic sepsis and, 488-493
treatment of, with exogenous surfactant, metabolic considerations in, 91-92
Adrenal cortex disorders, pulmonary manifestations of, 649-650
 β -Adrenergic agonists aerosols, for measuring bronchodilator response, 159-160
 β -Adrenergic antagonists, pulmonary side effects due to, 577-578
Adult respiratory distress syndrome (ARDS), clinical syndrome of, 492-493
sepsis and, 490-491
Agammaglobulinemia, X-linked, features of, 508-510
Age, advanced, and respiratory infection in systemic illness, 475-477
effect on clinical presentation of pneumonia, 475
effect on DLCO, 191
in predictions of normal values for PFTs, 136-137
and tuberculosis, 302-304
AIDS. See *Acquired immunodeficiency syndrome*.
Airway, colonization of, mechanisms of, 471-472
risk factors for, 471
and systemic illness, 470-472
obstruction of, in systemic lupus erythematosus, 688-689
upper, obstruction of, and respiratory function, 523-524
Airway disease, 711-712
in rheumatoid arthritis, 700-702
in Sjögren's syndrome, 711-712
Alcoholism, respiratory infection in, 478-479
Allergic angitis, and granulomatosis, 667-668
Allergy(ies), testing for, bronchoprovocation testing in, 174
Altitude, in predictions of normal values for PFTs, 139
Alveolar-capillary surface, fluid transport at, physiology of, 561-562
Alveolar epithelial cells, type II, role of ion channels in, 30-31
Alveolar macrophages, role of ion channels in, 31-32
Alveolar oxygen concentration and altitude, effect on DLCO, 191
American Thoracic Society (ATS), recommendations of, for spirometry, 148-149
Amikacin, in treatment of tuberculosis, 359
drug-resistant, 349
Aminoglycosides, in treatment of tuberculosis, 359
Amiodarone pulmonary toxicity, 574-577
Amyloidosis, pulmonary involvement in, 742
pulmonary manifestations of, 670-671
Anastomosis, portopulmonary, in chronic liver disorders, 598
Anemia, sickle cell, pulmonary involvement in, 730-733
Antibiotics, for respiratory tract infections in systemic illness, 487-488
Antigen challenge, for measuring bronchial hyperresponsiveness, 169
Antimycobacterial agents, 355-364
 α_1 -Antitrypsin deficiency, in chronic liver disorders, 603-605
molecular replacement therapy for, 123-124
Apnea, CNS abnormalities and, 522-523
posthyperventilation, in CNS diseases, 528-529
Apneusis, in CNS diseases, 530

- ARDS. *See Adult respiratory distress syndrome.*
- Arm ergometry, for exercise testing, 278
- Arthritis, rheumatoid, 697-703
- airway disease in, 700-702
 - evaluation of, with bronchoalveolar lavage and lung gallium scanning, 714
 - inflammation in, 698-700
 - necrobiotic nodules in, 700
 - pleural involvement in, 697-698
 - pulmonary interstitial fibrosis in, 698-700
 - pulmonary vasculitis in, 702
 - respiratory disease in, major histocompatibility patterns with, 702-703
 - respiratory infection in, 480
 - unusual pulmonary associations or complications in, 702
- Aspiration, of gastrointestinal contents, 622-629
- Aspirin challenge, for detection of acute bronchospasm in asthmatics, 171
- Asthma, confirmation of, bronchoprovocation testing in, 172-173
- factitious, diagnosis of, bronchoprovocation testing in, 174
 - occupational, challenge testing in, 170-172
 - substances associated with, 171
 - role of eicosanoids in, 100-101
- Ataxia, in CNS diseases, 530
- Ataxia-telangiectasia, immunodeficiency with, features of, 515
- Athletes, respiratory function of, effects of training on, 139
- Atrial septal defects, pulmonary vascular disease in, 557
- ATS. *See American Thoracic Society.*
- Autonomic nervous system, function in respiration, 536-537
- Azithromycin (CP-62933), in treatment of tuberculosis, 359
- Azathioprine, for respiratory tract infections in systemic illness, 488
- BACTEC procedure, for detection of *Mycobacterium tuberculosis*, 317-318
- Behavior, compliance, in tuberculosis therapy, action steps for improvement of, 376-379
- factors affecting, 375-376
- Behcet's disease, 668
- Bischloroethylnitrosourea (BCNU), metabolism of, 55-56
- Bleomycin, metabolism of, 50-53
- Blood diseases. *See Hematologic disorders.*
- Blood gas instruments, 227-229
- Blood gas tensions and pH, effect on pulmonary metabolic function, 6
- Blood gases, arterial, 227-237. *See also Blood sample.*
- Blood sample, analysis of, 231-235
- data calculation in, 231-233
 - data transmission in, 233
 - proficiency testing programs for, 235-236
 - quality control process in, 233-235
 - contamination of, minimization of, 230
 - procurement of, 229-231
 - transport, cooling, and delay of, 230
- Blood volume, in evaluation of endothelial injury in human lung, 14-16
- Body plethysmography, for measurement of lung volumes, 179-180
- Body position, effect on DLCO, 192
- Bone, sarcomas of, metastasis to lung, 774-775
- Bone marrow transplantation, in hematologic malignancy-associated disorders, pulmonary involvement in, 742
- respiratory infection in, 483-484
- Breast, carcinoma of, metastasis to lung, 771-773
- Bronchial hyperresponsiveness, measurement of, methods of, 167-170
- nonspecific, diseases associated with, 172
 - pathogenesis of, 165-167
- Bronchial inhalation challenge techniques, 167-172
- Bronchiolitis, and rheumatoid arthritis, 700-701
- Bronchoalveolar lavage, for evaluation of collagen vascular diseases, 712-714
- Bronchodilators, response to, 155-164
- clinical implications of, 160-162
 - criteria for, 161
 - measurement of, agents for, 159-160
 - partial flow-volume curves for, 157-158
 - physiologic tests for, 155-157
 - plethysmography for, 158
 - variability of, 159
- Bronchoprovocation testing, 165-176
- for allergy testing, 174
 - clinical uses of, 172-174
 - for confirmation of asthma diagnosis, 172-173
 - for diagnosis of factitious asthma, 174
 - in diagnosis of reactive airways dysfunction syndrome, 173-174
 - for evaluation of pulmonary symptoms, 173
 - techniques of, 167-172
- Calcium, influx of, in endothelial cells, 33
- Cancer. *See also specific types.*
- respiratory infection in, 482
- Caplan's syndrome, 700
- Capreomycin, in treatment of tuberculosis, 328
- drug-resistant, 349
- Carbon dioxide, content of, calculation of, 261
- end-tidal, 251
 - noninvasive monitoring of, 250-251
 - response to, in assessment of ventilatory control, 220-222
- Carbon dioxide pressure, arterial, estimation of, 260-261
- mixed venous, measurement of, 256-260
- Carbon dioxide rebreathing methods, for measurement of cardiac output, 255-264
- Carbon monoxide diffusing capacity (DLCO), 187-197
- alteration of, factors causing, 195
 - clinical applications of, 194-196
 - in evaluation of impairment from respiratory disorders, 196
 - measurement of, 188-190
 - interpretation of data in, 190-192
 - laboratory issues in, 190
 - single-breath techniques for, 189
 - morphometric, 190
 - prediction of normal values of, 192-194
 - rebreathing, 189-190
 - steady-state, 189
- Carboxyhemoglobin, effect on DLCO, 191-192
- Cardiac disease, and alteration in pulmonary function testing, 567-571
- alterations in pulmonary vasculature due to, 545-550
 - pleural manifestations of, 571-574
 - pulmonary and pleural complications of, 545-592
- Cardiac output, measurement of, by carbon dioxide rebreathing methods, 255-264
- in non-steady-state conditions, 261-263
- Cardiopulmonary exercise testing, 277-291
- Cartilage hair hypoplasia, features of, 506-507
- Celiac disease, pulmonary manifestations of, 630

- Central inspiratory neuromuscular drive, assessment of, 216–217
- Central nervous system, function in respiration, 521–531
- Central nervous system diseases, abnormal breathing patterns in, 528–530
- Central respiratory neural drive, assessment of, 216 measurements of, 218–219
- Central respiratory neuromuscular drive, measurements of, 219–220
- Cerebellar atrophy, and respiratory function, 530
- Cerebral cortex, damage to, and respiratory function, 526–528
- Cervix, carcinoma of, metastasis to lung, 771
- CGP 7040, in treatment of tuberculosis, 357–358
- Charcot-Marie-Tooth disease, effect on respiratory system, 534–536
- Chemical drive, measurements of, 220–224
- Chemotherapy, for tuberculosis, background of, 342–343. See also *Tuberculosis, treatment of*
- Cheyne-Stokes respiration, in CNS diseases, 529
- Chloride channels, in tracheal epithelial cells, 27–29
- Cholangitis, primary sclerosing, in chronic liver disorders, 605
- Churg-Strauss disease, 667–668
- Cigarette smoke, effect on mucociliary clearance of particulate matter, 30
- Ciprofloxacin, in treatment of drug-resistant tuberculosis, 350
- Cirrhosis, primary biliary, pulmonary manifestations of, 601–603
- pulmonary manifestations of, 594–598
- Clara cells, ion transport in, 30
- Clofazimine, in treatment of tuberculosis, 358
- Closed-circuit helium dilution, for measurement of lung volumes, 177–179
- CNS. See *Central nervous system*.
- Coagulation disorders, and the lungs, 724–730
- Cold air isocapnic hyperventilation challenge test, for measuring bronchial hyperresponsiveness, 169
- Colitis, ulcerative, pulmonary manifestations of, 629
- Collagen vascular diseases, evaluation of, with bronchoalveolar lavage and lung gallium scanning, 712–714
- pulmonary manifestations of, 677–722
- respiratory infection in, 479–480
- Colon, carcinoma of, metastasis to lung, 768–769
- Congenital heart disease, and abnormalities in pulmonary function, 570–571
- as cause of pulmonary vascular disease, 550–560
- Congestive heart failure, chronic, abnormalities in pulmonary function testing in, 567–570
- transudative effusions caused by, 572–573
- Connective tissue disease, mixed, pulmonary involvement in, 708–709
- Correctional institutions (prisons), tuberculosis in, 402–404
- Corticosteroids, for respiratory tract infections in systemic illness, 488
- for systemic lupus erythematosus pleuritis, 679–681
- CQG (gangamicin), in treatment of tuberculosis, 360
- Crohn's disease, pulmonary manifestations of, 629
- Cutaneous infections, mycobacterial, 419–429
- Cycle ergometer, for exercise testing, 278
- protocols for, 279–280
- Cyclophosphamide, metabolism of, 54–55
- for respiratory tract infections in systemic illness, 488
- for Wegener's granulomatosis, 666–667
- Cycloserine, in treatment of tuberculosis, 328
- drug-resistant, 350
- Cyclosporine, for respiratory tract infections in systemic illness, 488
- Cystic fibrosis, treatment of, molecular biology in, 152–123
- Diabetes mellitus, pulmonary manifestations of, 650–651 and respiratory function, 537
- respiratory infection in, 477–478
- and tuberculosis, 309
- Diaphragm, role in respiratory muscle function, 199–200, 208–211
- DiGeorge syndrome, features of, 505–506
- Dihydromyocyclanecin A, in treatment of tuberculosis, 360
- Disseminated intravascular coagulation, treatment of, 728–729
- Diurnal variation, effect on DLCO, 192
- DLCO. See *Carbon monoxide diffusing capacity (DLCO)*.
- DNA cloning, 120–121
- DNA dissociation, 120
- DNA expression libraries, role in diagnosis and treatment of pulmonary disease, 121–122
- DNA structure, 119
- Dressler's syndrome, clinical manifestations and treatment of, 573–574
- Drug-susceptibility tests, for identification of *Mycobacterium* species, 319–320
- Dwarfism, short-limbed, immunodeficiency with, features of, 506–507
- Dyscrasias, plasma cell, pulmonary involvement in, 741–742
- Eicosanoids, in control of normal lung function, 96–101
- in lung injury, 101–102
- lung metabolism of, 95–105
- measurement of, 97–98
- role in asthma and increased airway reactivity, 100–101
- role in control of lung circulation, 99–100
- treatment of lung disease by, 102–103
- Eisenmenger's syndrome, pulmonary vascular disease in, 557–558
- Elderly, tuberculosis in, 397–401
- Ellipsoid technique, for measurement of lung volumes, 180
- Emphysema, effect on pulmonary metabolic function, 5–6
- Endocarditis, right-sided, 579–584
- bacteriology of, 579–580
- clinical manifestations of, 580–581
- etiology of, 579
- prognosis of, 585
- treatment of, 581–585
- Endocrine diseases, pulmonary manifestations of, 645–653
- Endometrium, carcinoma of, metastasis to lung, 771
- Endoscopic sclerotherapy, pulmonary, complications of, in patients with liver disease, 606
- Endothelial cells, role of ion channels in, 32–33
- Endothelial injury, in human lung, evaluation of, 13–24
- endothelial metabolic functions in, 18–22
- endothelial permeability in, 16–18
- vascular and extravascular volumes, 14–16
- Endothelial metabolic functions, in evaluation of endothelial injury in human lung, 18–22
- Endothelial permeability, in evaluation of endothelial injury in human lung, 16–18
- Endotracheal tubes, for respiratory tract infections in systemic illness, 488
- Environment, in prevention of tuberculosis, 367–368

- ARDS. See *Adult respiratory distress syndrome*.
- Arm ergometry, for exercise testing, 278
- Arthritis, rheumatoid, 607-703
- airway disease in, 700-702
 - evaluation of, with bronchoalveolar lavage and lung gallium scanning, 714
 - inflammation in, 698-700
 - necrotic nodules in, 700
 - pleural involvement in, 697-698
 - pulmonary interstitial fibrosis in, 698-700
 - pulmonary vasculitis in, 702
 - respiratory disease in, major histocompatibility patterns with, 702-703
 - respiratory infection in, 480
 - unusual pulmonary associations or complications in, 702
- Aspiration, of gastrointestinal contents, 622-629
- Aspirin challenge, for detection of acute bronchospasm in asthmatics, 171
- Asthma, confirmation of, bronchoprovocation testing in, 172-173
- factitious, diagnosis of, bronchoprovocation testing in, 174
 - occupational, challenge testing in, 170-172
 - substances associated with, 171
 - role of eicosanoids in, 100-101
- Ataxia, in CNS diseases, 530
- Ataxia-telangiectasia, immunodeficiency with, features of, 515
- Athletes, respiratory function of, effects of training on, 139
- Atrial septal defects, pulmonary vascular disease in, 557
- ATS. See *American Thoracic Society*.
- Autonomic nervous system, function in respiration, 536-537
- Aztreomycin (CP-62933), in treatment of tuberculosis, 359
- Azathioprine, for respiratory tract infections in systemic illness, 488
- BAC1EC procedure, for detection of *Mycobacterium tuberculosis*, 317-318
- Behavior, compliance, in tuberculosis therapy, action steps for improvement of, 376-379
- factors affecting, 375-376
- Behcet's disease, 668
- Bischloroethylnitrosourea (BCNU), metabolism of, 55-56
- Bleomycin, metabolism of, 50-53
- Blood diseases. See *Hematologic disorders*.
- Blood gas instruments, 227-229
- Blood gas tensions and pH, effect on pulmonary metabolic function, 6
- Blood gases, arterial, 227-237. See also *Blood sample*.
- Blood sample, analysis of, 231-235
- data calculation in, 231-233
 - data transmission in, 233
 - proficiency testing programs for, 235-236
 - quality control process in, 233-235
 - contamination of, minimization of, 230
 - procurement of, 229-231
 - transport, cooling, and delay of, 230
- Blood volume, in evaluation of endothelial injury in human lung, 14-16
- Body plethysmography, for measurement of lung volumes, 179-180
- Body position, effect on DLCO, 192
- Bone, sarcomas of, metastasis to lung, 774-775
- Bone marrow transplantation, in hematologic malignancy-associated disorders, pulmonary involvement in, 742
- respiratory infection in, 483-484
 - Breast, carcinoma of, metastasis to lung, 771-773
 - Bronchial hyperresponsiveness, measurement of, methods of, 167-170
 - nonspecific, diseases associated with, 172
 - pathogenesis of, 165-167
- Bronchial inhalation challenge techniques, 167-172
- Bronchiolitis, and rheumatoid arthritis, 700-701
- Bronchoalveolar lavage, for evaluation of collagen vascular diseases, 712-714
- Bronchodilators, response to, 155-164
- clinical implications of, 160-162
 - criteria for, 161
 - measurement of, agents for, 159-160
 - partial flow-volume curves for, 157-158
 - physiologic tests for, 155-157
 - plethysmography for, 158
 - variability of, 159
- Bronchoprovocation testing, 165-176
- for allergy testing, 174
 - clinical uses of, 172-174
 - for confirmation of asthma diagnosis, 172-173
 - for diagnosis of factitious asthma, 174
 - in diagnosis of reactive airways dysfunction syndrome, 173-174
 - for evaluation of pulmonary symptoms, 173
 - techniques of, 167-172
- Calcium, influx of, in endothelial cells, 33
- Cancer. See also specific types.
- respiratory infection in, 482
- Caplan's syndrome, 700
- Capreomycin, in treatment of tuberculosis, 328
- drug-resistant, 349
- Carbon dioxide, content of, calculation of, 261
- end-tidal, 251
 - noninvasive monitoring of, 250-251
 - response to, in assessment of ventilatory control, 220-222
- Carbon dioxide pressure, arterial, estimation of, 260-261
- mixed venous, measurement of, 256-260
- Carbon dioxide rebreathing methods, for measurement of cardiac output, 255-264
- Carbon monoxide diffusing capacity (DLCO), 187-197
- alteration of, factors causing, 195
 - clinical applications of, 194-196
 - in evaluation of impairment from respiratory disorders, 196
 - measurement of, 188-190
 - interpretation of data in, 190-192
 - laboratory issues in, 190
 - single-breath techniques for, 189
 - morphometric, 190
 - prediction of normal values of, 192-194
 - rebreathing, 189-190
 - steady-state, 189
- Carboxyhemoglobin, effect on DLCO, 191-192
- Cardiac disease, and alteration in pulmonary function testing, 567-571
- alterations in pulmonary vasculature due to, 545-550
 - pleural manifestations of, 571-574
 - pulmonary and pleural complications of, 545-592
- Cardiac output, measurement of, by carbon dioxide rebreathing methods, 255-264
- in non-steady-state conditions, 261-263
- Cardiopulmonary exercise testing, 277-291
- Cartilage hair hypoplasia, features of, 506-507
- Celiac disease, pulmonary manifestations of, 630

- Central inspiratory neuromuscular drive, assessment of, 216-217
- Central nervous system, function in respiration, 521-531
- Central nervous system diseases, abnormal breathing patterns in, 528-530
- Central respiratory neural drive, assessment of, 216 measurements of, 218-219
- Central respiratory neuromuscular drive, measurements of, 219-220
- Cerebellar atrophy, and respiratory function, 530
- Cerebral cortex, damage to, and respiratory function, 526-528
- Cervix, carcinoma of, metastasis to lung, 771
- CCP 7040, in treatment of tuberculosis, 357-358
- Charcot-Marie-Tooth disease, effect on respiratory system, 534-536
- Chemical drive, measurements of, 220-224
- Chemotherapy, for tuberculosis, background of, 342-343. See also *Tuberculosis, treatment of*
- Cheyne-Stokes respiration, in CNS diseases, 529
- Chloride channels, in tracheal epithelial cells, 27-29
- Cholangitis, primary sclerosing, in chronic liver disorders, 605
- Churg-Strauss disease, 667-668
- Cigarette smoke, effect on mucociliary clearance of particulate matter, 30
- Ciprofloxacin, in treatment of drug-resistant tuberculosis, 350
- Cirrhosis, primary biliary, pulmonary manifestations of, 601-603 pulmonary manifestations of, 594-598
- Clara cells, ion transport in, 30
- Clofazimine, in treatment of tuberculosis, 358
- Closed-circuit helium dilution, for measurement of lung volumes, 177-179
- CNS. See *Central nervous system*.
- Coagulation disorders, and the lungs, 724-730
- Cold air isocapnic hyperventilation challenge test, for measuring bronchial hyperresponsiveness, 169
- Colitis, ulcerative, pulmonary manifestations of, 629
- Collagen vascular diseases, evaluation of, with bronchoalveolar lavage and lung gallium scanning, 712-714 pulmonary manifestations of, 677-722 respiratory infection in, 479-480
- Colon, carcinoma of, metastasis to lung, 768-769
- Congenital heart disease, and abnormalities in pulmonary function, 570-571 as cause of pulmonary vascular disease, 550-560
- Congestive heart failure, chronic, abnormalities in pulmonary function testing in, 567-570 transudative effusions caused by, 572-573
- Connective tissue disease, mixed, pulmonary involvement in, 708-709
- Correctional institutions (prisons), tuberculosis in, 402-404
- Corticosteroids, for respiratory tract infections in systemic illness, 488 for systemic lupus erythematosus pleuritis, 679-681
- CQQ (gangamicin), in treatment of tuberculosis, 360
- Crohn's disease, pulmonary manifestations of, 629
- Cutaneous infections, mycobacterial, 419-429
- Cycle ergometer, for exercise testing, 278 protocols for, 279-280
- Cyclophosphamide, metabolism of, 54-55 for respiratory tract infections in systemic illness, 488 for Wegener's granulomatosis, 666-667
- Cycloserine, in treatment of tuberculosis, 328 drug-resistant, 350
- Cyclosporine, for respiratory tract infections in systemic illness, 488
- Cystic fibrosis, treatment of, molecular biology in, 122-123
- Diabetes mellitus, pulmonary manifestations of, 650-651 and respiratory function, 537 respiratory infection in, 477-478 and tuberculosis, 309
- Diaphragm, role in respiratory muscle function, 199-200, 208-211
- DiGeorge syndrome, features of, 505-506
- Dihydromyocapnecin A, in treatment of tuberculosis, 360
- Disseminated intravascular coagulation, treatment of, 728-729
- Diurnal variation, effect on DLCO, 192
- DLCO. See *Carbon monoxide diffusing capacity (DLCO)*.
- DNA cloning, 120-121
- DNA dissociation, 120
- DNA expression libraries, role in diagnosis and treatment of pulmonary disease, 121-122
- DNA structure, 119
- Dressler's syndrome, clinical manifestations and treatment of, 573-574
- Drug-susceptibility tests, for identification of *Mycobacterium* species, 319-320
- Dwarfism, short-limbed, immunodeficiency with, features of, 506-507
- Dyscrasias, plasma cell, pulmonary involvement in, 741-742
- Eicosanoids, in control of normal lung function, 96-101 in lung injury, 101-102 lung metabolism of, 95-105 measurement of, 97-98 role in asthma and increased airway reactivity, 100-101 role in control of lung circulation, 99-100 treatment of lung disease by, 102-103
- Eisenmenger's syndrome, pulmonary vascular disease in, 557-558
- Elderly, tuberculosis in, 397-401
- Ellipsoid technique, for measurement of lung volumes, 180
- Emphysema, effect on pulmonary metabolic function, 5-6
- Endocarditis, right-sided, 579-584 bacteriology of, 579-580 clinical manifestations of, 580-581 etiology of, 579 prognosis of, 585 treatment of, 581-585
- Endocrine diseases, pulmonary manifestations of, 645-653
- Endometrium, carcinoma of, metastasis to lung, 771
- Endoscopic sclerotherapy, pulmonary, complications of, in patients with liver disease, 606
- Endothelial cells, role of ion channels in, 32-33
- Endothelial injury, in human lung, evaluation of, 13-24 endothelial metabolic functions in, 18-22 endothelial permeability in, 16-18 vascular and extravascular volumes, 14-16
- Endothelial metabolic functions, in evaluation of endothelial injury in human lung, 18-22
- Endothelial permeability, in evaluation of endothelial injury in human lung, 16-18
- Endotracheal tubes, for respiratory tract infections in systemic illness, 488
- Environment, in prevention of tuberculosis, 367-368

- Environmental exposures, in predictions of normal values for PFTs, 138-139
- Erythrocyte disorders, pulmonary involvement in, 730-735
- Esophageal atresia, pulmonary manifestations of, 617-619
- Esophageal disease, pulmonary manifestations of, 619-622
- Ethambutol, in treatment of tuberculosis, 326-327
- Ethionamide, in treatment of tuberculosis, 327-328
drug-resistant, 349-350
- Ethnic groups, tuberculosis among, 304-305
- Exercise, arterial desaturation during, prediction of, 195-196
effect on DLCO, 192
- Exercise challenge, for measuring bronchial hyperresponsiveness, 169-170
- Exercise testing, cardiopulmonary, assessment of symptoms during, 285
- equipment for, 289
- stage I, 280-285
- stage 4, 288-289
- stages 2 and 3, 285-288
- Exercise tests, protocols for, 279-280
types of, 277-279
- Felty's syndrome, respiratory infection in, 480
- Fick principle, 255
- First-order kinetics, effect on pulmonary metabolic function, 3-4
- Flow-volume curves, definition of, 146
partial, for measuring bronchodilator response, 157-158
spirometry and, 145-154
- Folate antagonists, in treatment of tuberculosis, 359-360
- Free radical injury, cellular protection from, 41-42
- Free radical production, mechanisms of, 38-39
by paraquat, 45
- Free radicals, effects on lung metabolism, 37-47
sources of, 39-41
- Fulminant hepatic failure, pulmonary manifestations of, 593-594
- Fusidic acid, in treatment of tuberculosis, 360-361
- Gallium scanning, lung, for evaluation of collagen vascular diseases, 712-714
- Gangamycin (CQQ), in treatment of tuberculosis, 360
- Gas dilution techniques, for measurement of lung volumes, 177-179
closed-circuit helium dilution technique, 177-179
open-circuit nitrogen washout technique, 179
- Gastrointestinal disease, aspiration and, 622-629
pulmonary manifestations of, 617-643
- Germ cell tumors, metastasis to lung, 765-767
- Goodpasture's syndrome, 655-661
clinical manifestations of, 657-658
pathogenesis of, 656-657
pathology and diagnosis of, 658-660
radiographic manifestations of, 658
therapy and prognosis of, 660-661
- Granulomatosis, lymphomatoid. See *Lymphomatoid granulomatosis*.
- Wegener's. See *Wegener's granulomatosis*.
- Guillain-Barré syndrome, effect on respiratory system, 534-535
- Head and neck cancer, metastasis to lung, 773-774
- Heart, septic pulmonary emboli arising from, 579-584
- Heart disease, respiratory infection in, 482
- Heart-lung transplantation, respiratory infection in, 485-486
- Heart transplantation, respiratory infection in, 485
- Height, in predictions of normal values for PFTs, 136
- Hematologic disorders, effect on lungs, 723-746
malignancy-associated, in bone marrow transplantation, pulmonary involvement in, 742
immunosuppression in, 738-739
infection in, 738-739
mediastinal compression/mass effect on, 736-737
pulmonary infiltration in, 737-738
pulmonary involvement in, 736-742
- Hemeoprotein peroxidases, role in oxidative insult to lung, 79
- Hemoglobin concentration, effect on DLCO, 191
- Hemoglobopathies, associated with abnormal oxygen affinities, pulmonary involvement in, 734
- Hemophilia, treatment of, 728
- Hemoptysis, pulmonary, 724-729. See also *Pulmonary hemorrhage*.
- Hemorrhage, pulmonary. See *Pulmonary hemorrhage*.
- Hepatitis, chronic active, pulmonary manifestations of, 605
- Hepatocellular carcinoma, metastasis to lung, 770
- Hereditary disorders, pulmonary manifestations of, 636-638
- Histamine challenge, for measuring bronchial hyperresponsiveness, 168-169
- HIV infection. See *Human immunodeficiency virus infection*.
- Homeless shelters, tuberculosis in, 404
- 5-HT. See *5-Hydroxytryptamine*.
- Human immunodeficiency virus (HIV) infection, effect on immunity, 507-508
effect on tuberculosis patients in prisons, 404
mycobacterial disease in patients with, 445-463
role in expression of tuberculosis, 307-308, 446-447
- Hydralazine, as cause of lupuslike syndrome, 694-695
- 5-Hydroxytryptamine (5-HT), lung metabolism of, 59-70.
See also *Serotonin*.
- Hyperimmunoglobulin E syndrome (Job's syndrome), features of, 516
- Hyperleukocytosis, pulmonary involvement in, 736-737
- Hypertension, left atrial, effect on pulmonary metabolic function, 5
pulmonary, in chronic liver disorders, 600-601
histologic changes in, 551-555
pulmonary venous, as cause of pulmonary vascular disease, 560-567
- Hyperthyroidism, pulmonary manifestations of, 647-648
- Hyperventilation, central neurogenic, in CNS diseases, 529-530
- Hypothyroidism, pulmonary manifestations of, 645-647
- Hypoventilation, central alveolar, CNS abnormalities and, 523
- Hypoxia, response to, in assessment of ventilatory control, 222-224
- Immune cells, in tuberculosis, 445-446
- Immune response, components of, 503-505
- Immunity, cell-mediated, defects in, 505-508
acquired primary disorders, 507-508
congenital disorders, 505-507
humoral, defects in, 508-512
acquired, 512
congenital, 508-512

- Immunodeficiency, with ataxia-telangiectasia, features of, 515
with elevated IgM levels, features of, 510
- Immunodeficiency disorders, severe combined, features of, 515-516
- Immunodeficiency states, congenital and acquired, pulmonary consequences of, 503-519
- Immunomodulators, in treatment of tuberculosis, 361
- Immunosuppression, in hematologic malignancy-associated disorders, 739
- Infection. See also specific types of infections.
in hematologic malignancy-associated disorders, 739
pulmonary. See *Pulmonary infection*.
- Infection control, in pulmonary function testing, 130-132
- Infectious diseases, pulmonary manifestations of, 671
- Inflammation, in rheumatoid arthritis, 698-700
- Inflammatory bowel disease, sulfasalazine for, pulmonary complications of, 629-630
- Intercostal muscles, role in respiratory muscle function, 200
- Interstitial lung disease, DLCO in, 194
in Sjögren's syndrome, 712
- Intestinal disease, pulmonary manifestations of, 629-630
- Ion channels, in alveolar macrophages, 31-32
in Clara cells, 30
in endothelial cells, 32-33
in metabolic regulation of respiratory cells, 25-36
in tracheal epithelial cells, 26-30
in type II alveolar epithelial cells, 30-31
- Ipratropium bromide, for measuring bronchodilator response, 160
- Ischemia and reperfusion injury, role of xanthine oxidase in, 75-79
- Isoniazid, in prevention of tuberculosis, 369-371, 372-373
in treatment of tuberculosis, 324-325
- Jails, tuberculosis in, 404
- Job's syndrome, features of, 516
- Kanamycin, in treatment of tuberculosis, 328
drug-resistant, 349
- β-Lactams**, in treatment of tuberculosis, 359
- Liposome encapsulation, of new antimycobacterial agents, 361-362
- Liver diseases, chronic, 594-605
respiratory infection in, 478-479
effect on interpretation of pulmonary function tests, 605-607
pulmonary aspects of, 593-607
- Liver function, effect of liver transplantation on, 609-611
- Liver transplantation, effect on liver function, 609-611
pulmonary aspects of, 607-611
postoperative complications, 608-609
pretransplant pulmonary evaluation, 607-608
respiratory infection in, 485
- Long-term care facilities, tuberculosis in, 401-402
- Lung, anatomy and physiology of, 723-724
coagulation disorders and, 724-730
endothelial injury in, evaluation of, 13-24. See also *Endothelial injury, in human lung, evaluation of*
hematologic disorders affecting, 723-746. See also *Pulmonary hemorrhage* and specific disorders.
- hematologic malignancies affecting, 736-742. See also *Hematologic disorders*.
host defense of, components of, 504
5-HT uptake and metabolism in, 61-62
metabolic functions of, interpretation of, 1-12
issue on, 1-125. See also *Pulmonary metabolic functions*.
- nonpulmonary malignancies in, metastatic spread of, 747-807. See also *Lung disease, metastatic*.
oxidative insult to, role of heme protein peroxidases in, 79
- role of mitochondrial electron transport in, 71-72
role of phagocyte NADPH oxidase in, 73-75
- Lung antioxidant enzymatic defenses, 41
- Lung cancer, primary, metastatic lung cancer vs, 753-754
and scleroderma, 705
treatment of, molecular biology in, 122
- Lung circulation, role of eicosanoids in control of, 99-100
- Lung disease, combined, lung volume measurements in, 184
- 5-HT uptake in, applications and limitations of measuring, 67-68
- interstitial, DLCO in, 194
- metastatic, pulmonary and pleural manifestations of, 747-807
- mycobacterial, 423-428
- Mycobacterium avium* and *Mycobacterium kansasii* as cause of, 432-433
- obstructive, DLCO in, 194
lung volume measurements in, 182-183
pathophysiology of, role of 5-HT in, 65-67
restrictive, lung volume measurements in, 183-184
treatment of, by manipulation of eicosanoid system, 102-103
- Lung inflation, effect on pulmonary metabolic function, 6
- Lung injury, effects on 5-HT uptake, 63-65
oxygen, in humans, 43-44
role of eicosanoids in, 101-102
- Lung metabolism, of eicosanoids, 95-105
free radical effects on, 37-47
paraoxon poisoning and, 45
of serotonin, 59-70
of xenobiotic compounds, 49-58
- Lung volume, effect on DLCO, 191
measurement of, 177-186
body plethysmography for, 179-180
clinical application of, 182-184
closed-circuit helium dilution technique for, 177-179
comparison of different techniques, 180-181
open-circuit nitrogen washout technique for, 179
radiographic techniques for, 180
normal predictive values for, 181-182
- Lupus syndrome, drug-induced, 578-579
- Lymphadenitis, superficial mycobacterial, in children and adolescents, 386, 413-414
- Lymphomatoid granulomatosis, 668-669
- Macrolides, in treatment of tuberculosis, 358-359
- Malnutrition, respiratory infection in, 486-487
- Medulla oblongata, destruction of, and respiratory function, 522-527
- Melanomas, malignant, metastasis to lung, 765
- Meningitis, in children and adolescents, 387
- Mental hospitals, tuberculosis in, 401-402
- Metabisulfite challenge, for detection of acute bronchospasm in asthmatics, 171
- Metabolic diseases, pulmonary manifestations of, 645-653
- Metabolic regulation of respiratory cells, ion channels in, 25-36

- Metastasis. See *Neoplasm metastasis*.
- Methacholine inhalation challenge, for measuring bronchial hyperresponsiveness, 168
- Methotrexate, metabolism of, 56
- Microembolism, effect on pulmonary metabolic function, 5-6
- Mineral metabolism, abnormalities of, pulmonary manifestations of, 651
- Mitochondrial electron transport, role in oxidative insult to lung, 71-72
- Mitral stenosis, hemoptysis due to, 566-567
natural history of, 563-564
pulmonary vascular disease due to, 562-567
etiology of, 565-566
following surgical correction, 565
histologic changes, 564-565
- Mixed-order conditions, effect on pulmonary metabolic function, 3-4
- Molecular replacement therapy, for α_1 -antitrypsin deficiency, 123-124
- Mouth occlusion pressure, measurements of, 220
- Multiple sleep latency test, for evaluation of respiratory disorders during sleep, 266, 269-271
- Myasthenia gravis, effect on respiratory system, 535
- Mycobacterial disease, diagnosis of, 433-435
in HIV-infected patients, 445-463
issue on, 297-463
- nontuberculous, epidemiology of, 407-417
of lymph node, 414
prevalence of disease, 411-412
prevalence of infection, 410-411
pulmonary, 412-414
of skin and soft tissues, 414-415
transmission of, 408-410
- nontuberculous mycobacteria as cause of, disseminated, 415
- Mycobacterial infection, molecular immunology of, 121
nontuberculous, in AIDS, 456-460
clinical features of, 458-459
diagnosis of, 459
treatment of, 459-460
- Mycobacteriology laboratory, in diagnosis of tuberculosis, 315-322
- BACTEC procedure, 317-318
- drug-susceptibility tests, 319-320
- genetic and immunologic probes, 318-319
- mycolic acid patterns, 319
- routine procedures, 316-317
- Mycobacterium avium* complex, as cause of disease, 431-432
clinical characteristics of, 432-433
management and treatment of, 436-439
- Mycobacterium avium* complex infection, immune cells in, and role of HIV, 458
- Mycobacterium cheloneae*, as cause of cutaneous and pulmonary infections, 419-429
cutaneous disease caused by, 420-422
disseminated disease caused by, 422-423
microbiology of, 419-420
pulmonary disease caused by, 423-428
- Mycobacterium fortuitum*, as cause of cutaneous and pulmonary infections, 419-429
cutaneous disease caused by, 420-422
disseminated disease caused by, 422-423
microbiology of, 419-420
pulmonary disease caused by, 423-428
- Mycobacterium fortuitum* complex, management and treatment of, 440
- Mycobacterium kansasii*, clinical characteristics of, 432-433
- Mycobacterium kansasii* disease, management and treatment of, 439-440
- Mycobacterium malmoense*, as cause of disease, 440
- Mycobacterium marinum*, management and treatment of, 440
- Mycobacterium simiae*, as cause of disease, 440
- Mycobacterium tuberculosis*, diagnosis of, 433-435
management and treatment of, 435-436
mycobacteriophage types of, 320
- Mycobacterium tuberculosis* complex, 315-316
treatment of, new antimycobacterial agents for, 355-364
- Mycobacterium ulcerans*, as cause of disease, 440
- Mycobacterium xenopi*, as cause of disease, 440
- Mycolic acids, pattern of, for identification of *Mycobacterium* species, 319
- Myeloma, multiple, pulmonary involvement in, 741-742
- Myeloproliferative disorders, chronic, pulmonary involvement in, 734-736
- Myotonia congenita, effect on respiratory system, 536
- Myotonic muscular dystrophy, effect on respiratory system, 536
- NADPH cytochrome P₄₅₀ reductase, role in microsomal mixed function oxidase system, 72-73
- Narcolepsy, 273-274
- Nasogastric tubes, for respiratory tract infections in systemic illness, 488
- Neoplasm metastasis, pleural, 776-794
clinical manifestations of, 783-788
diagnosis of, 788-790
etiology and incidence of, 776-777
pathogenesis of, 777-783
prognosis of, 790
treatment of, 790-794
process of, biology of, 747-752
pulmonary, 774-775
detection of, by imaging, 754-755
growth rates of, determined by imaging techniques, 755-756
malignant melanomas and, 765
primary lung cancer vs., 753-754
radiographic patterns of, 756-775
tissue diagnosis of, techniques for obtaining, 764-765
treatment of, 775-776
- Neurologic disorders, and respiration, 521-543
management of, 537-538
- Nezelof's syndrome, features of, 506
- Nitrofurantoin, metabolism of, 53-54
- Nonsteroidal anti-inflammatory drugs (NSAIDs), for respiratory tract infections in systemic illness, 487
- Nucleic acid, cloning of, in diagnosis and treatment of tuberculosis, 119-121
- Nursing homes, tuberculosis in, 399-401
- Obstructive lung disease, DLCO in, 194
lung volume measurements in, 182-183
- Open-circuit nitrogen washout, for measurement of lung volumes, 179
- Osmotic challenge, for measuring bronchial hyperresponsiveness, 170
- Ovaries, carcinoma of, metastasis to lung, 770-771
- Oxidant/antioxidant metabolism, 49-50
- Oxidant injury, molecular sites of, 42-43

- Oximetry, definition of, 242-243
 non-pulse transmission, 244-245
 noninvasive, 242-250
 pulse, 245-250
 clinical experience with, 248-250
 dyshemoglobin in, 246-248
 historical development of, 245-246
- Oxygen, noninvasive monitoring of, 239-250
 clinical experience with, 240-241
 historical developments of, 239-240
 practical considerations in, 240
- Oxygen lung injury, in humans, 43-44
- Oxygen uptake, maximal, measurement of, during exercise, 280
- PAF.** See *Platelet activating factor*.
- Pancreas, carcinoma of, metastasis to lung, 770
- Pancreatitis, pulmonary manifestations of, 630-636
- Para-aminosalicylic acid, in treatment of tuberculosis, 327
 drug-resistant, 350
- Paraquat, free radical production by, 45
- Parquat poisoning, and lung metabolism, 45
 treatment of, 45-46
- Parathyroid disorders, pulmonary manifestations of, 648-649
- Parkinsonism, and respiratory function, 530
- Patent ductus arteriosus, pulmonary vascular disease in, 557
- D-Penicillamine, for scleroderma pulmonary disease, 705-706
- Perfused vascular surface area, effect on pulmonary metabolic function, 4-7
- Peripheral nervous system, function in respiration, 531-536
- Peripheral neuromuscular control, neuropathologic conditions and, 533-536
- PFT.** See *Pulmonary function testing*.
- Phagocyte NADPH oxidase, role in oxidative insult to lung, 73-75
- Phenazimes, in treatment of tuberculosis, 358
- Pituitary disorders, pulmonary manifestations of, 649
- Planimetry method, for measurement of lung volumes, 180
- Plasma exchange therapy, for Goodpasture's syndrome, 660-661
- Platelet activating factor, 109-110
 biologic activities of, 108-109
 biosynthesis of, 107-108
 effects on pulmonary function, 110-113
 in pulmonary pathobiology, 107-118
 pulmonary vascular alterations caused by, 113-115
 role in pulmonary disease, 115
 structure of, 107
- Plethysmography, for measuring bronchodilator response, 158
 respiratory-inductive, 251
- Pleura, involvement of, in rheumatoid arthritis, 697-698
 in systemic lupus erythematosus, 678-681
- Pleural effusions, in chronic liver disorders, 600
 malignant, 777-783
 diagnosis of, 788-790
 prognosis of, 790
 paramalignant, 777-783
 systemic lupus erythematosus, diagnosis of, 679
- Pleural space, physiology of, 571-572
- Pleural "spiders", in chronic liver disorders, 599
- Pleuritis, systemic lupus erythematosus, treatment of, 679-681
- Pleuropulmonary disease, cardiovascular drugs and, 574-579
- Pneumococcosis, rheumatoid, 700
- Pneumonia, aspiration, predisposing factors for, 624
 clinical presentation of, effects of systemic illness and age on, 475
- Pneumocystis carinii*, in HIV-infected patients, 507
 in systemic illness, clinical conditions causing, 475-488
 See also *Respiratory tract infections*.
 epidemiology of, 472-475
- Pneumonitis, drug-induced, 739-741
 interstitial, lymphocytic, in Sjögren's syndrome, 712
 lupus, acute, treatment of, 685
- Polyangiitis overlap syndrome, 668
- Polychondritis, relapsing, 710-711
- Polycythemia, pulmonary involvement in, 735-736
- Polymyositis/dermatomyositis, pulmonary involvement in, 706-708
- Postcardiac injury syndrome, clinical manifestations and treatment of, 573-574
- Posture, during testing, in predictions of normal values for PFTs, 138
- Potassium channels, in alveolar macrophages, 31-32
 in endothelial cells, 33
 in tracheal epithelial cells, 29-30
 in type II alveolar epithelial cells, 30-31
- Predicted normal values, in pulmonary function testing, 135-143
 accuracy of, factors affecting, 136-139
 future considerations, 141-142
 importance of, 135-136
 lower limits of normal in, 140-141
 recommendations for testing, 141
 selection of subjects for reference, 139-140
 in trained athletes, singers, and wind instrument players, 139
- Prednisone, for Wegener's granulomatosis, 667
- Pregnancy, changes during, effect on DLCO, 192
- Prisons, tuberculosis in, 402-404
- Probes, in diagnosis of tuberculosis, 318-319
- Procainamide, as cause of lupuslike syndrome, 694-695
 as cause of lupus syndrome, 578-579
- Prostate carcinoma, metastasis to lung, 767
- Pulmonary artery ligation, effect on pulmonary metabolic function, 5-6
- Pulmonary disease, applications of molecular biology to, 119-125
 role of PAF in, 115
- Pulmonary edema, neurogenic, and respiratory function, 525-527
- Pulmonary emboli, septic, causes of, 579
- Pulmonary embolism, clinical presentation, evaluation and treatment, 728-730
- Pulmonary fibrosis, interstitial, in rheumatoid arthritis, 698-700
- Pulmonary function, abnormalities in, congenital heart disease and, 570-571
- Pulmonary function laboratory, 129-134
 infection control and safety in, 130-132
 instrumentation in, 132
 personnel in, 129-130
 quality control in, 132-133
- Pulmonary function testing, abnormalities in, with chronic congestive heart failure, 567-570
 applications of, 135
 in assessment of respiratory muscle function, 204-205
 infection control and safety in, 130-132
 interpretation of, effect of chronic liver diseases on, 605-607

- Pulmonary function testing (*Continued*)
 issue on, 129-291
 prediction of normal values in, 135-143
 in scleroderma, 703-705
- Pulmonary function tests, types of, 145-146
- Pulmonary hemorrhage, 724-728
 clinical presentation of, 724-725
 diagnostic evaluation of, 727
 differential diagnosis of, 725-727
 treatment of, 727-728
- Pulmonary hypertension, in chronic liver disorders, 600-601
- Pulmonary infection, mycobacterial, 419-429
 in systemic lupus erythematosus, 692-693
- Pulmonary metabolic functions, clinical observations of, 9
 effect of acute lung injury on, 7-9
 effect of alveolar and blood gas tensions and pH on, 6
 effect of emphysema on, 5-6
 effect of left atrial hypertension on, 5
 effect of lung inflation on, 5-6
 effect of microembolism on, 5-6
 effect of postnatal development of pulmonary microcirculation on, 6-7
 effect of pulmonary artery ligation on, 5-6
 factors affecting, 3-4
 influence of surface area on, 4-7
 in the intact organ, measurement of, 2-3
 interpretation of, 1-12
 issue on, 1-125
- Pulmonary microcirculation, postnatal development of, effect on pulmonary metabolic function, 6-7
- Pulmonary oxygen toxicity, therapy for patients exposed to, 44-45
- Pulmonary-renal syndromes, 655-675
 classification of, 656
 general approach to, 671
- Pulmonary surfactant metabolism, 83-93
- Pulmonary symptoms, evaluation of, bronchoprovocation testing in, 173
- Pulmonary vascular damage, causes of, 559-560
- Pulmonary vascular disease, in atrial septal defects, 557
 congenital disease and, 550-560
 in Eisenmenger's syndrome, 557-558
 in patent ductus arteriosus, 557
 in pulmonary vascular resistance, 558-559
 pulmonary venous hypertension and, 560-567
 in tetralogy of Fallot, 560
 in ventricular septal defects, 556-557
- Pulmonary vascular endothelium, role in 5-HT uptake, 62-63
- Pulmonary vascular resistance, pulmonary vascular disease in, 558-559
- Pulmonary vasculature, alterations in, cardiac disease and, 545-550
 normal, anatomy of, 546
 function of, 546-550
- Pulmonary vasculitis, in rheumatoid arthritis, 702
- Pyrazinamide, in treatment of tuberculosis, 326
- 4-Quinolones, in treatment of tuberculosis, 356-357
- Race, in predictions of normal values for PFTs, 137-138
- Radiography, for measurement of lung volumes, 180
- Reactive airways dysfunction syndrome, diagnosis of, bronchoprovocation testing in, 173-178
- Reactive oxygen metabolites, metabolic success of, during oxidant stress and ischemia with perfusion, 71-81
- Rectum, carcinoma of, metastasis to lung, 768-769
- Renal cell carcinoma, metastasis to lung, 767-768
- Renal disease, pulmonary manifestations of, 671
- Renal failure, respiratory infection in, 480-482
- Renal transplantation, respiratory infection in, 484-485
- Reproductive systemic disorders, pulmonary manifestations of, 650
- Respiration, CNS function in, 521-531
 neural control of, 521-522
 neurologic disorders and, 521-543
 peripheral nervous system in, 531-536
- Respiratory cells, metabolic regulation of, ion channels in, 25-36
- Respiratory disease, manifestations of, caused by systemic lupus erythematosus, 677-697. See also *Systemic lupus erythematosus*.
- Respiratory disorders, during sleep, evaluation of, 265-276. See also *Sleep, respiratory disorders during, evaluation of*.
- Respiratory function, effect of endocrine and metabolic disorders on, 645-653
 neuropathologic conditions and, 522-531
- Respiratory illness, gastrointestinal causes of, 617-643
- Respiratory muscle control, 531-533
- Respiratory muscle function, clinical and physiologic evaluation of, 199-214
 anatomical considerations, 199
 for determining endurance, 207-208
 for determining strength, 205-207
 history and physical examination in, 204
 diaphragmatic contribution to, evaluation of, 208-211
 role of abdominal muscles in, 201
 role of diaphragm in, 199-200
 role of intercostal muscles in, 200
 role of scalene muscles in, 200-201
 role of sternocleidomastoid muscles in, 201
- Respiratory muscles, coordination of, 202-203
 evaluation of, history and physical examination in, 204
 physiology and metabolism of, 201-202
 in systemic lupus erythematosus, 689-691
- Respiratory tract, defense mechanism of, normal, 469-470
- Respiratory tract infections, and acute lung injury, in systemic illness, 469-502
 in alcoholism, 478-479
 in cancer, 482
 in chronic liver disease, 478-479
 in collagen vascular diseases, 479-480
 in diabetes mellitus, 477-478
 in Felty's syndrome, 480
 in heart disease, 482
 in malnutrition, 486-487
 in renal failure, 480-482
 in rheumatoid arthritis, 480
 in Sjögren's syndrome, 480
 in systemic illness, advanced age and, 475-477
 treatment of, 487-488
 in systemic lupus erythematosus, 479-480
 in transplantation, 483-486
- Restrictive lung diseases, lung volume measurements in, 183-184
- Rifabutin, in treatment of tuberculosis, 357
- Rifampin, drug-resistant, 350-351
 in treatment of tuberculosis, 325-326, 357
- Rifamycins, in treatment of tuberculosis, 357-358
- Rifapentine, in treatment of tuberculosis, 357
- RNA probes, role in diagnosis and treatment of pulmonary disease, 121
- Roxithromycin (RU-28965), in treatment of tuberculosis, 358-359

- Scalene muscles, role in respiratory muscle function, 200–201
- Scleroderma, 703–706
 evaluation of, with bronchoalveolar lavage and lung gallium scanning, 714
 lung cancer and, 705
 lymphocytic interstitial pneumonitis in, in Sjögren's syndrome, 712
 pulmonary complications of, 705
 pulmonary function testing in, 703–705
 respiratory disease in, treatment of, 705–706
- Sclerosis, systemic, progressive. See *Scleroderma*.
- Seizures, pulmonary complications of, 527–528
- Sepsis, definition of, 489
 effects on acute lung injury, 493
 as a risk factor for ARDS, 490–491
 systemic, and acute lung injury, 488–493
 clinical syndrome of, 492–493
 pathology of, 491–492
 and indirect lung injury, mechanisms of, 491
 respiratory effects of, 489–490
- Serotonin (5-HT), lung metabolism of, 59–70
 role in pathophysiology of lung disease, 65–67
 synthesis, distribution, and physiology of, 59–61
- Serotonin (5-HT) uptake, effects of lung injury on, 63–65
 in lung disease, applications and limitations of measuring, 67–68
 and metabolism in normal lung, 61–62
 role of pulmonary vascular endothelium in, 62–63
- Sex, in predictions of normal values for PFTs, 137
- and tuberculosis, 304
- Short-term maximal power output, cardiopulmonary, 280
- Shy-Drager syndrome, and respiratory function, 536–537
- Sickle cell anemia, pulmonary involvement in, 730–733
- Single-breath techniques, for assessing DLCO, 189
- Sjögren's syndrome, 711–712
 evaluation of, with bronchoalveolar lavage and lung gallium scanning, 714
 interstitial lung disease in, 712
 respiratory infection in, 480
- Skin disease, nontuberculous mycobacteria as cause of, 414
- Sleep, respiratory disorders during, evaluation of, 265–276
 continuous nasal positive airway pressure treatment for, 269
 interpretation of results, 273–274
 monitoring techniques for, 266–269
 multiple sleep latency test for, 266, 269–271
 routine respiratory sleep study for, 269
 types of studies, 266
- Smoking, effect on DLCO, 192
 history of, in predictions of normal values for PFTs, 138 and tuberculosis, 309
- Sodium transport, in tracheal epithelial cells, 29
- Soft tissue, sarcomas of, metastasis to lung, 774–775
- Soft-tissue disease, nontuberculous mycobacteria as cause of, 414
- Spastic dysphonia, and respiratory function, 524–525
- Spinal cord injury, cervical, and respiratory function, 530–531
- Spirometers, accuracy of, 149–150
 ATS recommendations for, 148–149
 quality control of, 150
 types of, performance by, 150–151
- Spirometry, and flow-volume curves, 145–154
 reference values in, selection of, 152–153
 results of, interpretation of, 153
 test selection and reporting of results, 151–152
- volume-time versus flow volume, 146
- Spondylitis, ankylosing, pulmonary involvement in, 709–710
- Step tests, for exercise testing, 278–279
- Sternocleidomastoid muscles, role in respiratory muscle function, 201
- Steroids, treatment with, and risk of tuberculosis, 309
- Streptomycin, in treatment of tuberculosis, 327
- Sulfasalazine, for inflammatory bowel disease, pulmonary complications of, 629–630
- Sulfonamides, in treatment of tuberculosis, 359–360
- Surface tension in lung, role of surfactant in, 85
- Surfactant, components of, 83–85
 endogenous, turnover and metabolism of, 85–89
 exogenous, acute lung injury with, metabolic considerations in treatment of, 91–92
 turnover and metabolism of, 89–90
- phospholipid composition in, 83–84
- pool sizes of, 89
- regulation of pool size, 89
- role in reducing surface tension, 85
- subfractions of, 84–85
- turnover times of, 90–91
- "whole", isolation of, 83
- Surfactant-associated proteins, 84
- Systemic disease, airway colonization and, 470–472
 effect on clinical presentation of pneumonia, 475
 pneumonia in, epidemiology of, 472–475. See also *Pneumonia, in systemic illness*.
- pulmonary manifestations of, issue on, 469–818
- respiratory infection in, clinical conditions causing, 475–488
- respiratory infections and acute lung injury in, 469–502
- Systemic lupus erythematosus, airway in, 688–689
 drug-induced, manifestations of respiratory disease caused by, 693–695
- evaluation of, with bronchoalveolar lavage and lung gallium scanning, 714
- immunologic subsets in, 696–697
- lung parenchyma in, 681–687
- lung vasculature in, 687–688
- manifestations of respiratory disease caused by, 677–679
 clinical evaluation of patients with, 695–696
 indirect, 691–693
- pleura in, 678–681
- relation of lung involvement to other organ involvement in, 696–697
- respiratory infection in, 479–480
- respiratory muscles in, 688–691
- Tetralogy of Fallot, pulmonary vascular disease in, 560
- Thalassemias, pulmonary involvement in, 733–734
- Thioacetazone, in treatment of tuberculosis, 328–329
- Thoracic disease, noninfectious, in systemic lupus erythematosus, 693
- Thrombocythemia, pulmonary involvement in, 735
- Thrombosis, clinical presentation, evaluation, and treatment of, 729–730
- Thyroid, carcinoma of, metastasis to lung, 769–770
- Thyroid disorders, pulmonary manifestations of, 645–648
- Tocainide pulmonary toxicity, 577
- Tonometers, in analysis of blood, 235
- Tracheal epithelial cells, role of ion channels in, 26–30
- Transplantation, bone marrow, in hematologic malignancy-associated disorders, pulmonary involvement in, 742
- respiratory infection in, 483–486
- Treadmill, for exercise testing, 278
 protocols for, 279
- Trimethoprim, in treatment of tuberculosis, 359–360

- Tuberculosis, abdominal, in children and adolescents, 388
 in AIDS, 447-456
 - clinical features of, 447-448
 - diagnosis of, 448-454
 - epidemiology of, 447
 - preventive therapy for, 455-456
 - treatment of, 455
 among the elderly, 397-401
 - clinical and radiographic presentations, 398
 - diagnosis of, 398
 - in nursing homes, 399-401
 - treatment of, 398-399
 asymptomatic primary, in children and adolescents, 384
 bone and joint, in children and adolescents, 387-388
 cases and rates of, 301
 - geographic locations, 301-302
 in children and adolescents, 381-395
 - diagnosis of, 389-390
 - epidemiology of, 381-382
 - management of, 390-394
 - primary infection, clinical picture of, 384-386
 - pathogenesis of, 382-384
 cloning of nucleic acid in diagnosis and treatment of, 119-121
 community problems related to, 397-406
 in correctional institutions (prisons), 402-404
 - clinical and radiographic presentations, 403
 - effect of HIV infection on, 404
 - treatment of, 403-404
 diagnosis of, role of clinician in, 298
 - role of mycobacteriology laboratory in, 315-322
 disease sites of, 299
 drug-resistant, 341-353
 - effects of resistance on therapy outcome, 347-348
 - management of multiply resistant cases, 348-349
 - mechanism of resistance, 343-347
 - surgery for, 351
 - treatment of, chemotherapeutic regimens for, 348-351
 - resistance to, 351-352
 endobronchial, in children and adolescents, 384-385
 epidemiology of, and AIDS, 308-309
 - and HIV infection, 308-309
 - in US, 297-313
 extrapulmonary, treatment of, 334-335
 extrathoracic, in children and adolescents, 386-389
 of eye and ear, in children and adolescents, 389
 genitourinary, in children and adolescents, 388
 immune cells in, 445-446
 infectiousness of, 299-301
 in long-term care and mental hospitals, control of, 401-402
 meningeal, in children and adolescents, 387
 miliary, in children and adolescents, 386-387
 morbidity reporting of, 297-299
 Mycobacterium species as cause of, 315-316
 prevention of, environmental control in, 367-368
 - future of, 373-374
 - physician's role in, 365-374
 - administering preventive therapy, 369-371
 - development of strategies, 365-367
 - identifying candidates for preventive treatment, 371-372
 - limiting further transmission, 367-368
 - managing preventive therapy, 372-373
 - prescribing preventive therapy, 372
 - protecting uninfected persons, 368-369
 progressive primary pulmonary, in children and adolescents, 385-386
 risk factors for, 302-309, 367
 role of HIV infection in, 446-447
 screening in, 309-311
 - high-risk environments, 310-311
 - high-risk occupations, 310
 - low-income populations, 310
 - in shelters for the homeless, 404
 - in short-term facilities (jails), 404
 of the skin, in children and adolescents, 388-389
 treatment of, chemotherapeutic regimens in, 329-332
 - background of, 342-343
 - ensuring adherence to, 333
 - evaluating response to, 333-334
 - monitoring of, 332-333
 current regimens, 323-339
 drug delivery systems for, 361-362
 enhancement of patient compliance, 375-380. See also *Behavior, compliance, in tuberculosis therapy*.
 first-line drugs in, 324-327
 new antimycobacterial agents for, 355-364
 second-line drugs in, 327-328
- Uremia, pulmonary manifestations of, 670
- Vascular diseases, collagen. See *Collagen vascular diseases*.
- DLCO in, 194-195
- Vasculitis, systemic necrotizing, 661
- Vasoconstriction, impaired hypoxic pulmonary, in chronic liver disorders, 599-600
- Ventilation, neurophysiologic aspects of, 215-216
- and ventilatory pattern, measurements of, 217-218
- Ventilation-perfusion mismatch, in chronic liver disorders, 599
- Ventilatory control, measurements of, carbon dioxide and hypoxia in, 220-224
- clinical application of, 224-225
- Ventilatory monitoring, in sleep studies, 268-269, 271-273
- Ventilatory regulation, measurements of, 215-226
- Ventricular septal defects, pulmonary vascular disease in, 556-557
- Volume-time curves, definition of, 146
- von Willebrand's disease, treatment of, 728
- Waldenstrom's macroglobulinemia, pulmonary involvement in, 741-742
- Walking tests, for exercise testing, 279
- Wegener's granulomatosis, 661-667
- antineutrophil cytoplasmic antibodies in, 663-664
- clinical manifestations of, 661-663
- pathology and diagnosis of, 664-666
- radiologic features of, 664
- therapy and prognosis of, 666-667
- Weight, in predictions of normal values for PFTs, 137
- Whipple's disease, pulmonary manifestations of, 630
- Wiskott-Aldrich syndrome, features of, 512-514
- Xanthine oxidase, role in ischemia and reperfusion injury, 75-79
- Xenobiotic compounds, lung metabolism of, 49-58

